Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases
Sumel Ashique,Gabriele De Rubis,Ekta Sirohi,Neeraj Mishra,Mohd Rihan,Ashish Garg,Ruby-Jean Reyes,Bikash Manandhar,Shvetank Bhatt,Niraj Kumar Jha,Thakur Gurjeet Singh,Gaurav Gupta,Sachin Kumar Singh,Dinesh Kumar Chellappan,Keshav Raj Paudel,Philip M Hansbro,Brian G Oliver,Kamal Dua
DOI: https://doi.org/10.1016/j.cbi.2022.110231
2022-12-01
Abstract:The human microbiota is fundamental to correct immune system development and balance. Dysbiosis, or microbial content alteration in the gut and respiratory tract, is associated with immune system dysfunction and lung disease development. The microbiota's influence on human health and disease is exerted through the abundance of metabolites produced by resident microorganisms, where short-chain fatty acids (SCFAs) represent the fundamental class. SCFAs are mainly produced by the gut microbiota through anaerobic fermentation of dietary fibers, and are known to influence the homeostasis, susceptibility to and outcome of many lung diseases. This article explores the microbial species found in healthy human gastrointestinal and respiratory tracts. We investigate factors contributing to dysbiosis in lung illness, and the gut-lung axis and its association with lung diseases, with a particular focus on the functions and mechanistic roles of SCFAs in these processes. The key focus of this review is a discussion of the main metabolites of the intestinal microbiota that contribute to host-pathogen interactions: SCFAs, which are formed by anaerobic fermentation. These metabolites include propionate, acetate, and butyrate, and are crucial for the preservation of immune homeostasis. Evidence suggests that SCFAs prevent infections by directly affecting host immune signaling. This review covers the various and intricate ways through which SCFAs affect the immune system's response to infections, with a focus on pulmonary diseases including chronic obstructive pulmonary diseases, asthma, lung cystic fibrosis, and tuberculosis. The findings reviewed suggest that the immunological state of the lung may be indirectly influenced by elements produced by the gut microbiota. SCFAs represent valuable potential therapeutic candidates in this context.